Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a ...
For the first time in Sierra Leone’s history, citizens have been subjected to the most disgraceful and insulting press release from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback